Literature DB >> 17010381

Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.

Elena Gustchina1, John M Louis, Carole A Bewley, G Marius Clore.   

Abstract

The human immunodeficiency virus type-1 (HIV-1) envelope (Env) proteins that mediate membrane fusion represent a major target for the development of new AIDS therapies. Three classes of Env-mediated membrane fusion inhibitors have been described that specifically target the pre-hairpin intermediate conformation of gp41. Class 2 inhibitors bind to the C-terminal heptad repeat (C-HR) of gp41. The single example of a class 3 inhibitor targets the trimeric N-terminal heptad repeat (N-HR) of gp41 and has been postulated to sequestrate the N-HR of the pre-hairpin intermediate through the formation of fusion incompetent heterotrimers. Here, we show that N(CCG)-gp41, a class 2 inhibitor, and N36(Mut(e,g)), a class 3 inhibitor, synergistically inhibit Env-mediated membrane fusion for several representative HIV-1 strains (X4 and R5) in both a cell fusion assay (with membrane-bound CD4) and an Env-pseudo-typed virus neutralization assay. The mechanistic, as well as potential therapeutic, implications of these observations for HIV-Env-mediated membrane fusion are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010381      PMCID: PMC1785329          DOI: 10.1016/j.jmb.2006.09.017

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  30 in total

Review 1.  The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection.

Authors:  E O Freed; M A Martin
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

2.  The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions.

Authors:  Takumi Koshiba; David C Chan
Journal:  J Biol Chem       Date:  2002-12-13       Impact factor: 5.157

3.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

4.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Theoretical aspects of specific and non-specific equilibrium binding of proteins to DNA as studied by the nitrocellulose filter binding assay. Co-operative and non-co-operative binding to a one-dimensional lattice.

Authors:  G M Clore; A M Gronenborn; R W Davies
Journal:  J Mol Biol       Date:  1982-03-15       Impact factor: 5.469

7.  Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.

Authors:  G B Karlsson; F Gao; J Robinson; B Hahn; J Sodroski
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.

Authors:  Carole A Bewley; John M Louis; Rodolfo Ghirlando; G Marius Clore
Journal:  J Biol Chem       Date:  2002-02-21       Impact factor: 5.157

9.  Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.

Authors:  Stephen A Gallo; G Marius Clore; John M Louis; Carole A Bewley; Robert Blumenthal
Journal:  Biochemistry       Date:  2004-06-29       Impact factor: 3.162

10.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more
  14 in total

1.  Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Authors:  Cajetan Dogo-Isonagie; Son Lam; Elena Gustchina; Priyamvada Acharya; Yongping Yang; Syed Shahzad-ul-Hussan; G Marius Clore; Peter D Kwong; Carole A Bewley
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.

Authors:  Chetan Sood; Mariana Marin; Ajit Chande; Massimo Pizzato; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

3.  Tulongicin, an Antibacterial Tri-Indole Alkaloid from a Deep-Water Topsentia sp. Sponge.

Authors:  Hong-Bing Liu; Gianluigi Lauro; Robert D O'Connor; Katheryn Lohith; Michelle Kelly; Patrick Colin; Giuseppe Bifulco; Carole A Bewley
Journal:  J Nat Prod       Date:  2017-08-24       Impact factor: 4.050

4.  Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.

Authors:  Kostyantyn D Bobyk; Sivakoteswara R Mandadapu; Katheryn Lohith; Christina Guzzo; Abhishek Bhargava; Paolo Lusso; Carole A Bewley
Journal:  Mol Pharm       Date:  2017-07-13       Impact factor: 4.939

5.  Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.

Authors:  Cajetan Dogo-Isonagie; Su-Lin Lee; Katheryn Lohith; Hongbing Liu; Sivakoteswara R Mandadapu; Sabrina Lusvarghi; Robert D O'Connor; Carole A Bewley
Journal:  Bioorg Med Chem       Date:  2016-03-03       Impact factor: 3.641

6.  Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.

Authors:  Connie Zhao; Amy M Princiotto; Hanh T Nguyen; Shitao Zou; Meiqing Lily Zhao; Shijian Zhang; Alon Herschhorn; Mark Farrell; Karanbir Pahil; Bruno Melillo; Somisetti V Sambasivarao; Cameron Abrams; Amos B Smith; Navid Madani; Joseph Sodroski
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

7.  Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer.

Authors:  T Dwight McGee; Hyun Ah Yi; William J Allen; Amy Jacobs; Robert C Rizzo
Journal:  Bioorg Med Chem Lett       Date:  2017-05-08       Impact factor: 2.823

8.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Authors:  Elena Gustchina; John M Louis; Christian Frisch; Francisco Ylera; Annette Lechner; Carole A Bewley; G Marius Clore
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

10.  A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains.

Authors:  Elena Gustchina; John M Louis; Son N Lam; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.